It is important to understand precisely how the insulin-GLUT4 pathway is perturbed in insulin resistance since insulin resistance is a major risk factor for the development of type 2 diabetes and other metabolic diseases, and there are currently no pharmaceutical interventions that target this pathway directly. The gene discussed is SLC2A4; the disease is metabolic disease.